Therapy Areas: Respiratory
Cleveland Diagnostics' IsoPSA Added to National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection
11 May 2022 - - US-based biotechnology company Cleveland Diagnostics, Inc's prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection (version 1.2022), the company said.

The NCCN panel now recommends the use of IsoPSA as an option to further define the probability of high-grade prostate cancer (Gleason score ≥ 3+4, Grade Group 2 or higher) prior to a first biopsy or after a negative biopsy.

IsoPSA is a non-invasive, blood-based test that has demonstrated in large, multicenter studies superior diagnostic accuracy and clinical utility when compared to prostate-specific antigen, the current standard of care in prostate cancer, in men being considered for prostate biopsy.

NCCN is a not-for-profit alliance of thirty-one leading cancer centers devoted to patient care, research, and education.

NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives.

The prostate cancer panel consists of an august group of reviewers including epidemiologists, internists, oncologists, pathologists, radiologists and urologists.

Cleveland Diagnostics, Inc., is a commercial-stage biotechnology company developing highly efficacious, lab-friendly, affordable diagnostics tests using proprietary technology to improve cancer diagnostics.

Its Solvent Interaction Analysis technology investigates protein biomarkers at the structural level (as opposed to overall biomarker concentration in blood), providing better and more direct insights regarding the protein origin on the cellular level, thus improving test specificity to the underlying disease process.

Its portfolio of non-invasive cancer diagnostics will be expanding from prostate cancer to breast cancer, lung cancer and multicancer tests, to maximize clinical performance and efficiencies, reducing costs to payors and the healthcare system.